Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Patients Older Than 65 Years With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial
Latest Information Update: 18 Sep 2021
At a glance
- Drugs WT1 peptide-loaded dendritic cell vaccine (Primary)
- Indications Acute myeloid leukaemia
- Focus Biomarker; Therapeutic Use
- Acronyms WIDEA
- 19 Jan 2021 Biomarkers information updated
- 13 Aug 2013 Planned End Date changed from 1 Oct 2017 to 1 Jul 2018 as reported by ClinicalTrials.gov.
- 24 Sep 2012 New trial record